WO2017016512A1 - Nouvelle forme cristalline du mésylate de masitinib et son procédé de préparation - Google Patents

Nouvelle forme cristalline du mésylate de masitinib et son procédé de préparation Download PDF

Info

Publication number
WO2017016512A1
WO2017016512A1 PCT/CN2016/092224 CN2016092224W WO2017016512A1 WO 2017016512 A1 WO2017016512 A1 WO 2017016512A1 CN 2016092224 W CN2016092224 W CN 2016092224W WO 2017016512 A1 WO2017016512 A1 WO 2017016512A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
preparation
methanesulfonate
crystal form
Prior art date
Application number
PCT/CN2016/092224
Other languages
English (en)
Chinese (zh)
Inventor
陈敏华
张炎锋
刁小娟
杨存波
张晓宇
Original Assignee
苏州晶云药物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州晶云药物科技有限公司 filed Critical 苏州晶云药物科技有限公司
Priority to CN201680000737.0A priority Critical patent/CN106794179A/zh
Publication of WO2017016512A1 publication Critical patent/WO2017016512A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Definitions

  • the invention relates to the field of chemical medicine, in particular to a new crystal form of macetinib mesylate and a preparation method thereof.
  • Marsetinib (a compound of formula I) is a novel orally administered tyrosine kinase inhibitor developed by AB Sciences that inhibits a limited number of kinase-targeted mast cells and macrophages. Based on its unique mechanism of action, Marsetini has the potential to develop a variety of diseases such as tumors, inflammatory diseases, and central nervous system.
  • the mesylate salt of masatinib is used in clinical research and is currently in clinical phase III.
  • AB Science will submit a conditional marketing approval application to the European Medicines Agency EMA for the treatment of amyotrophic lateral sclerosis (ALS) disease.
  • Drug polymorphism is a common phenomenon in drug development and an important factor affecting drug quality. Different crystal forms of the same drug may have significant differences in appearance, solubility, melting point, dissolution, bioavailability, etc., and may also have different effects on drug stability, bioavailability, and efficacy. Therefore, in the development of drugs, the issue of drug polymorphism should be fully considered.
  • the patent CN103342701A of AB Science discloses the mesylate salt of the compound of the formula (I). a polymorph (ie, Form I below) characterized by an X-ray diffraction pattern comprising 2 ⁇ values at about 7.269, 9.120, 11.038, 13.704, 14.481, 15.483, 15.870, 16.718, 17.087, 17.473, 18.224, 19.248, 19.441, 19.940, 20.441, 21.469, 21.750, 22.111, 23.319, 23.763, 24.120, 24.681, 25.754, 26.777, 28.975, 29.609, 30.073 with characteristic peaks, the crystal form Extremely high humidity, not conducive to drug storage.
  • the inventors of the present invention surprisingly discovered in the course of the research that there is also a stable, industrially produced crystal form of the macetinib mesylate salt. In order to keep the drug stable during preparation, storage and formulation development, it provides more and better choice for drug development.
  • the present invention provides a crystalline form A of a mesylate salt of the compound of the formula (I) (ie, Masitinib mesylate),
  • the X-ray powder diffraction pattern has characteristic peaks at 2theta values of 20.7 ° ⁇ 0.2 °, 18.2 ° ⁇ 0.2 °, and 21.1 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form A is still in 2theta
  • the values have characteristic peaks at 20.3 ° ⁇ 0.2 °, 23.6 ° ⁇ 0.2 °, and 11.5 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form A also has a characteristic peak at a 2theta value of 19.9 ° ⁇ 0.2 °, 29.6 ° ⁇ 0.2 °, and 10.5 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form A also has a characteristic peak at a 2theta value of 10.5 ⁇ 0.2° and/or 11.5 ° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of Form A also has a characteristic peak at a 2theta value of 18.6 ⁇ 0.2° and/or 27.4 ° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of Form A of the present invention is substantially as shown in FIG.
  • the crystal form A provided by the present invention is further characterized in that an endothermic peak starts to appear near the temperature of 108 ° C, and an exothermic peak starts to appear near the temperature of 178 ° C, and another endothermic peak starts to appear near the temperature of 232 ° C, and its DSC basically as shown in Figure 2.
  • the crystal form A provided by the present invention is further characterized in that it has a weight loss gradient of about 6.44% when heated to 100 ° C, and its TGA is substantially as shown in FIG. It can be calculated from the TGA chart that when heated to 100 ° C, Form A loses about 2 molecules of water.
  • Another object of the present invention is to provide a process for the preparation of Form A comprising the amorphous or solvate of the methanesulfonate salt of the compound of the formula (I) in a cyclic ether, an aromatic hydrocarbon, a halogenated hydrocarbon organic solvent or Crystallization is carried out in a mixed solvent with water.
  • the cyclic ether solvent is preferably 2-methyltetrahydrofuran.
  • the halogenated hydrocarbon solvent is preferably dichloromethane.
  • the means or manner of crystallization is preferably stirred and crystallized.
  • the methanesulfonate chloroform solvate of the compound of the formula (I) is suspended in 2-methyltetrahydrofuran, dichloromethane or a mixture of the two, stirred at 10 ° C or less, and centrifuged. The lower layer of solid was dried overnight at a constant temperature to obtain Form A.
  • the stirring is carried out at 5 ° C and below, for example 5 ° C.
  • Form A can be obtained by subjecting the methanesulfonate chloroform solvate of the compound of the formula (I) to humidity control-induced crystallization (transcrystallization). Further, humidity control induced crystallisation can be performed on an existing dynamic moisture adsorption tester, and the conditions employed can be the usual test conditions.
  • the selected initial humidity may be from 40% relative humidity to 80% relative humidity, and the selected endpoint humidity is from 90% relative humidity to 95% relative humidity.
  • the induction temperature selected is from 0 ° C to 40 ° C, more preferably from 20 ° C to 30 ° C.
  • the residence time of each humidity condition is not higher than 180 minutes, and the humidity change interval is not more than 10% relative humidity.
  • the preparation method of the present invention further comprises the step of suspending the amorphous methanesulfonate salt of the compound of the formula (I) in chloroform and stirring to obtain a methanesulfonate chloroform solvate of the compound of the formula (I).
  • the amorphous methanesulfonate of the compound of the formula (I) can be obtained by dissolving a crystalline form such as CN103342701A in a solvent such as methanol, ethanol or a mixed solvent thereof with other solvents, followed by rapid evaporation, and other solvents such as isopropyl.
  • a solvent such as methanol, ethanol or a mixed solvent thereof with other solvents
  • it can also be obtained by freeze-drying a product solution containing the methanesulfonate salt of the compound of the formula (I).
  • crystal or “crystal form” refers to the characterization by the X-ray diffraction pattern shown.
  • Those skilled in the art will appreciate that the physicochemical properties discussed herein can be characterized, with experimental error depending on the conditions of the instrument, the preparation of the sample, and the purity of the sample.
  • the X-ray diffraction pattern will generally vary with the conditions of the instrument. It is particularly important to note that the relative intensities of the X-ray diffraction patterns may also vary with experimental conditions, so the order of peak intensities cannot be the sole or decisive factor.
  • the experimental error of the peak angle is usually 5% or less, and the error of these angles should also be taken into account, and an error of ⁇ 0.2° is usually allowed.
  • the influence of experimental factors such as height will cause an overall shift in the peak angle, usually allowing a certain offset.
  • the X-ray diffraction pattern of one crystal form in the present invention need not be identical to the X-ray diffraction pattern in the examples referred to herein. Any crystal form having a map identical or similar to the characteristic peaks in these maps is within the scope of the present invention.
  • One skilled in the art will be able to compare the maps listed herein with a map of an unknown crystal form to verify whether the two sets of maps reflect the same or different crystal forms.
  • Crystal form and “polymorph” and other related terms are used in the present invention to mean that a solid compound exists in a specific crystalline state in a crystal structure.
  • the difference in physical and chemical properties of polymorphs can be reflected in storage stability, compressibility, density, dissolution rate and the like. In extreme cases, differences in solubility or dissolution rate can cause drug inefficiencies and even toxicity.
  • the novel crystalline form of the masatinib mesylate salt in the present invention, Form A is pure, unitary, and substantially free of any other crystalline form.
  • substantially free when used to refer to a new crystalline form means that the crystalline form contains less than 20% by weight of other crystalline forms, especially less than 10% by weight of other crystalline forms, more Other crystal forms of 5% by weight, more preferably less than 1% by weight of other crystal forms.
  • Polymorphic forms of the drug can be obtained by methods including, but not limited to, melt recrystallization, melt cooling, solvent recrystallization, solvent loss, rapid volatilization, rapid temperature drop, slow temperature drop, vapor diffusion, and sublimation. Sometimes, different methods may also achieve the same crystallization. Polymorphs can be obtained by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), optical microscopy, Hygroscopicity, etc. to detect, discover and classify.
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • optical microscopy Hygroscopicity, etc.
  • the crystal form adopted by the crystal form of the present invention is a crystal slurry method in which a supersaturated solution of a sample (in the presence of insoluble solids) is stirred and crystallized in a solvent system, and the crystallization time is usually 24-72 hours.
  • Another object of the present invention is to provide a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form A of a compound of formula (I) mesylate and a pharmaceutically acceptable adjuvant.
  • a therapeutically effective amount of Form A of the methanesulfonate salt of a compound of formula (I) is mixed or contacted with one or more pharmaceutical excipients to form a pharmaceutical composition or formulation in the pharmaceutical field.
  • the pharmaceutical composition may also comprise other crystalline forms or amorphous forms of pharmaceutically acceptable methicinib or a salt thereof, including, but not limited to, the known crystal forms disclosed in, for example, the patents CN103342701A and US20150166524 A1. .
  • the present invention also provides the use of the crystalline form A of the methanesulfonate salt of the compound of the formula (I) for the preparation of a pharmaceutical preparation for treating various diseases such as tumors, inflammatory diseases, and central nervous system.
  • the present invention also provides the use of the crystalline form A of the mesylate salt of the compound of the formula (I) or a pharmaceutical composition comprising the same for the treatment of diseases such as tumors, inflammatory diseases, central nervous system and the like.
  • the crystal form A of the compound of the formula (I) provided by the invention has a significantly lower wettability than the existing crystal form, and is convenient for preparation and long-term storage of the medicine, and has higher industrial application value.
  • Figure 1 is an XRPD pattern of the mesylate salt form A of the compound of formula (I)
  • Figure 2 is a DSC chart of the methanesulfonate salt form A of the compound of formula (I);
  • Figure 3 is a TGA diagram of the methanesulfonate salt form A of the compound of formula (I);
  • Figure 4 is a 1 H-NMR chart of the methanesulfonate salt form A of the compound of the formula (I);
  • Figure 5 is an infrared spectrum of the methanesulfonate crystal form A of the compound of the formula (I);
  • Figure 6 is a DVS dynamic moisture adsorption diagram of the methanesulfonate salt form A of the compound of formula (I);
  • Figure 7 is an XRPD pattern of the methanesulfonate crystal form A of the compound of the formula (I) before and after DVS (the upper graph is an XRPD pattern before DVS, and the lower graph is an XRPD pattern after DVS);
  • Figure 8 is an XRPD pattern of the methanesulfonate salt form A of the compound of the formula (I) before and after being placed at 5 ° C for 270 days (the upper graph is obtained before the test, and the lower graph is obtained after the test);
  • Figure 9 is an XRPD diagram of the compound (I) mesylate salt Form A before and after 270 days of standing at 25 ° C, 60% relative humidity. The figure is the pre-placement test, the lower figure is the test after placement;
  • Figure 10 is an XRPD pattern of the compound (I) mesylate salt form A before and after being placed at 40 ° C, 75% relative humidity for 270 days. The figure above shows the pre-placement test, and the lower figure shows the test after placement.
  • the starting material is the methanesulfonate salt of the compound of formula (I).
  • XRPD X-ray powder diffraction
  • DSC differential scanning calorimetry
  • the X-ray powder diffraction pattern of the present invention was collected on a Panalytical Empyrean X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of differential scanning calorimetry (DSC) according to the present invention are as follows: scan rate: 10 ° C / min; protective gas: nitrogen.
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q5000.
  • the method parameters of the thermogravimetric analysis (TGA) of the present invention are as follows: scan rate: 10 ° C / min; protective gas: nitrogen.
  • Example 1 The solid obtained in Example 1 was suspended in 15.0 mL of chloroform, stirred at 5 ° C for 24 hours, and the lower solid was removed by centrifugation, and dried at 25 ° C overnight.
  • the obtained solid was a chloroform solvate of the methanesulfonate salt of the compound of the formula (I).
  • the solvate temperature of the chloroform solvate is 130-150 °C.
  • the XRPD pattern of the crystal form A obtained in this example is shown in Fig. 1, and the X-ray powder diffraction data is shown in Table 1.
  • the DSC chart of Form A is shown in Fig. 2, the TGA chart is shown in Fig. 3, the NMR spectrum is shown in Fig. 4, and the infrared spectrum is shown in Fig. 5. among them:
  • the infrared spectrum peaks are as follows: 410.06, 456.14, 528.31, 582.75, 624.26, 675.17, 722.83, 762.33, 779.69, 806.04, 821.41, 858.11, 883.70, 916.75, 982.61, 1006.59, 1027.47, 1123.50 ,1176.82,1217.89,1277.78,1316.66,1357.31,1406.30,1448.99,1527.63,1558.05,1599.06,1665.09,2789.99,3260.24,3415.16.
  • the methanesulfonate crystal form A is induced by the humidity control to induce the chloroform solvate of the compound mesylate salt.
  • the specific operation is as follows: 60.2 mg of the chloroform solvate of the methanesulfonate salt of the compound of the formula (I) is placed in the dynamic moisture.
  • the experiment was started according to a preset humidity cycle, and the X-ray powder diffraction data of the solid obtained after the completion of the experiment are shown in Table 3, indicating that the solid was the crystal form A.
  • the dynamic moisture adsorption (DVS) experiment of the present invention was collected on an Intrinsic dynamic moisture adsorber manufactured by SMS Corporation (Surface Measurement Systems Ltd.), and the parameters used are shown in Table 4.
  • the dynamic moisture adsorption (DVS) test was carried out on the methanesulfonate crystal form disclosed in CN103342701A, and the moisture content at 80% relative humidity and 95% relative humidity is shown in Table 5.
  • the methanesulfonate crystal form A of the compound of the formula (I) of the present invention is placed at 5 ° C; 25 ° C, 60% relative humidity; and 40 ° C, 75% relative humidity, respectively, for 270 days, and X before and after the sample is placed.
  • Ray powder diffraction test the results are shown in Figure 8-10.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline A du mésylate de masitinib, son procédé de préparation et une utilisation médicale de celle-ci. L'hygroscopicité de la forme cristalline A est remarquablement réduite. Par conséquent, elle se révèle commode pour la préparation de médicaments et le stockage à long terme.
PCT/CN2016/092224 2015-07-29 2016-07-29 Nouvelle forme cristalline du mésylate de masitinib et son procédé de préparation WO2017016512A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680000737.0A CN106794179A (zh) 2015-07-29 2016-07-29 马赛替尼甲磺酸盐的新晶型及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510455391 2015-07-29
CN201510455391.0 2015-07-29

Publications (1)

Publication Number Publication Date
WO2017016512A1 true WO2017016512A1 (fr) 2017-02-02

Family

ID=57884105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/092224 WO2017016512A1 (fr) 2015-07-29 2016-07-29 Nouvelle forme cristalline du mésylate de masitinib et son procédé de préparation

Country Status (2)

Country Link
CN (1) CN106794179A (fr)
WO (1) WO2017016512A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177854A1 (fr) 2017-03-31 2018-10-04 Sandoz Ag Forme cristalline de masitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166524A1 (en) * 2013-12-18 2015-06-18 Sandoz Ag Crystalline form of masitinib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100491374C (zh) * 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
US8153792B2 (en) * 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166524A1 (en) * 2013-12-18 2015-06-18 Sandoz Ag Crystalline form of masitinib

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177854A1 (fr) 2017-03-31 2018-10-04 Sandoz Ag Forme cristalline de masitinib
US10961235B2 (en) 2017-03-31 2021-03-30 Sandoz Ag Crystalline form of masitinib

Also Published As

Publication number Publication date
CN106794179A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
JP5261487B2 (ja) ジヒドロプテリジノン誘導体の結晶形
WO2016184436A1 (fr) Nouvelle forme cristalline de sel de méthanesulfonate de lenvatinib et son procédé de préparation
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
WO2016110270A1 (fr) Nouvelle forme cristalline de maléate de nératinib et méthode de préparation de cette dernière
WO2016091221A1 (fr) Sel de composé de pyrrolo[2,3-d]pyrimidine et nouveau polymorphe de sel
WO2017193914A1 (fr) Formes cristallines de crisaborole sous forme libre et procédé de préparation et utilisation de celles-ci
WO2018184185A1 (fr) Cristal de sel d'addition d'ozanimod, procédé de préparation, composition pharmaceutique, et utilisations
BR112019021447A2 (pt) sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica
KR102516745B1 (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
WO2013132511A1 (fr) Nouveau polymorphe de chlorhydrate de lurasidone
AU2017373239B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
WO2018006870A1 (fr) Forme cristalline de galunisertib, son procédé de préparation et son utilisation
WO2018157803A1 (fr) Formes cristallines de vénétoclax et leur procédé de préparation
WO2016131406A1 (fr) Forme cristalline d'un inhibiteur oral des protéines kinases activées par des signaux mitogènes (mapk) et procédé de préparation de cette dernière
WO2017016512A1 (fr) Nouvelle forme cristalline du mésylate de masitinib et son procédé de préparation
WO2019134455A1 (fr) Nouvelle forme cristalline d'acalabrutinib, son procédé de préparation et son utilisation
WO2019165951A1 (fr) Forme cristalline d'un dérivé d'oxopicolinamide et son procédé de préparation
CN111732586B (zh) 含炔基化合物盐的晶型、制备方法及应用
US20220162185A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
WO2016004873A1 (fr) Forme cristalline d'un mésylate de dérivés nicotinamide, procédé de préparation associé, et application associée
WO2016110243A1 (fr) Forme cristalline d'un malate d'un inhibiteur de tyrosine kinase et procédé de préparation de ce dernier
US10544129B2 (en) Crystalline forms of AP26113, and preparation method thereof
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
WO2018001335A1 (fr) Formes cristallines de nbi-98854, procédé de préparation s'y rapportant et utilisation associée
WO2017152858A1 (fr) Forme cristalline de céritinib et procédé pour sa préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16829877

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16829877

Country of ref document: EP

Kind code of ref document: A1